Please assess the completion status of the following clinical trial:

Trial Title: Study of the Safety and Contraceptive Efficacy of C31G Compared to Conceptrol®

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Potential subjects must:~* Be healthy women, who are sexually active, at risk for pregnancy and desiring contraception.~* Be within the age range of 18 through 40 years inclusive.~* Be at low-risk for human immunodeficiency virus (HIV) or sexually transmitted disease (STD) infection and currently have a single sex partner (minimum 4 months) who is also at low-risk for HIV or STD.~* Have a negative urine pregnancy test prior to enrollment.~* Have normal cyclic menses with a usual length of 24 to 35 days over the last 2 cycles or at least one spontaneous, normal menstrual cycle (2 menses) since delivery, abortion, or after discontinuing hormonal contraception/hormonal therapy.~* Be willing to accept a risk of pregnancy.~* Be willing to engage in at least 4 acts of heterosexual vaginal intercourse per month for a period of 6 months.~* Be willing to be randomized to either study treatment.~* Be willing to only use the study product as the primary method of contraception over the course of the study with the exception of emergency contraception (EC), when indicated.~* Be capable of using the study product properly and agree to observe all study directions and requirements.~* Be willing to keep a diary to record coital information, product use information, information about the use of other vaginal products, and sign and symptom data of subject and partner.~* Agree not to participate in any other clinical trials during the course of the study.~* Be willing to give written informed consent to participate in the trial.~Exclusion Criteria:~Potential subjects must not:~* Have a history of allergy or sensitivity to spermicides or products containing N-9.~* Have had 3 or more urinary tract infections (UTI) in the past year.~* Have UTI by urine culture or symptomatic yeast vaginitis or symptomatic bacterial vaginosis diagnosed by wet mount unless treated and proof of cure is documented.~* Be pregnant, have a suspected pregnancy or desire to become pregnant during the course of the study.~* Have a history of infertility or of conditions that may lead to infertility, without subsequent intrauterine pregnancy.~* Have any contraindications to pregnancy (medical condition) or chronic use of category D or X medications.~* Have had more than one sexual partner in the last 4 months.~* Have shared injection drug needles within the past 12 months.~* Have or have been suspected to have HIV infection.~* Have been diagnosed with genital herpes simplex virus (HSV), with the first occurrence (initial episode) within three months prior to screening.~* Have 3 or more outbreaks of HSV within the last year.~* Have been diagnosed with any other STDs (including trichomonas) in the 6 months prior to the screening visit (with the exception of Human Papilloma Virus \[HPV\]).~* Be lactating or breastfeeding.~* Have any clinically significant abnormal vaginal bleeding or spotting within the month prior to screening.~* Have any clinically significant abnormal finding on pelvic examination or baseline labs, which in the view of the investigator, precludes her from participating in the trial.~* Have clinically significant signs of vaginal or cervical irritation on pelvic examination.~* Have had vaginal or cervical biopsy or vaginal surgery within 3 months prior to screening.~* Have used vaginal or systemic antibiotics or antifungals within 14 days prior to screening or randomization.~* Have had a Depo-Provera® injection in the 10 months prior to enrollment.~* Have an abnormal Pap smear with high grade squamous intraepithelial lesion (HSIL), atypical glandular cells (AGC) or ASC-H (atypical squamous cells, cannot exclude HSIL) within the last 12 months.~* Have an abnormal Pap smear with low-grade squamous intraepithelial lesion (LSIL) or ASCUS-HPV HR positive unless resolved by colposcopy.~* Have a Cervical Intraepithelial Neoplasia (CIN) diagnosis by biopsy within the last 12 months.~* Have a history or a current diagnosis of cervical cancer.~* Consume (on average) greater than three drinks of an alcoholic beverage per day.~* Have a past history (within twelve months) or current history of drug abuse \[recreational, prescription or over-the-counter (OTC)\].~* Have taken an investigational drug or used an investigational device within the past 30 days.~* Have previously participated in or completed this study or any other phase III study of C31G.~* Have issues or concerns (in the judgment of the investigator) that may compromise the safety of the subject or confound the reliability of compliance and information acquired in this study.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- A (Type: EXPERIMENTAL): C31G vaginal gel contains 35mg (1% concentration) of C31G in 3.5 mL volume of gel
- B (Type: ACTIVE_COMPARATOR): Conceptrol® Vaginal gel contains 100mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete